4OD.F · Odonate Therapeutics, Inc

-

Please sign in to comment on 4OD.F

1 Comment

Admin

3 years, 7 months ago

Odonate Therapeutics, Inc is currently in a long term downtrend where the price is trading 70.5% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Odonate Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 15.9% to $-32M since the same quarter in the previous year.

Finally, its free cash flow fell by 28.5% to $-32M since the same quarter in the previous year.

Based on the above factors, Odonate Therapeutics, Inc gets an overall score of 1/5.

Sector
Industry
ISIN	None
CurrencyCode	EUR
Exchange	F

Dividend Yield	0.0%
Beta	0.18
Target Price	4
PE Ratio	None
Market Cap	48M

ABOUT

Odonate Therapeutics, Inc

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.

4OD.F · Odonate Therapeutics, Inc

-

Odonate Therapeutics, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Odonate Therapeutics, Inc using a moving average strategy